Moderated by Dr. Chin-Sheng Hung, Director of Medical Affairs at Taipei Medical University Hospital, and presented by Dr. Wei-Wen Chang, Director of Surgery at Wan Fang Hospital, this lecture will explore how recurrence risk in HR+/HER2− early breast cancer extends beyond high-risk populations, highlighting the need for individualized treatment strategies that balance efficacy with long-term tolerability. The session will review the biological and clinical rationale for treatment escalation, including adjuvant CDK4/6 inhibitors, discuss the impact of treatment-related adverse events on treatment adherence and outcomes, and explore emerging challenges and therapeutic considerations in the post-progression setting.